Related Experiment Video
Updated: Jun 2, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Complement factor I in health and disease
Sara C Nilsson1, Robert B Sim, Susan M Lea
1Department of Laboratory Medicine, Medical Protein Chemistry, Lund University, Sweden.
Insights
Factor I (FI) regulates complement pathways by degrading C3b and C4b. FI deficiency causes severe infections, autoimmune diseases, or atypical hemolytic uremic syndrome.
Area of Science:
- Immunology
- Biochemistry
Background:
- Factor I (FI) is a key regulator of all complement pathways.
- It degrades activated complement proteins C3b and C4b with cofactor assistance.
Purpose of the Study:
- To summarize the role of Factor I in complement regulation.
- To describe the clinical consequences of Factor I deficiency.
- To detail the structure and enzymatic activity of Factor I.
Main Methods:
- Literature review of Factor I function and deficiency.
- Structural analysis of the Factor I heterodimer.
- Enzymatic activity assessment with natural and synthetic substrates.
Main Results:
- Complete FI deficiency leads to complement consumption, causing severe infections, glomerulonephritis, and autoimmune diseases.
- Incomplete FI deficiency is linked to atypical hemolytic uremic syndrome.
- FI is an 88kDa heterodimer with specific structural domains and cofactor-dependent enzymatic activity.
Conclusions:
- Factor I is essential for preventing complement-mediated pathology.
- FI deficiency has significant clinical implications, ranging from infections to severe systemic diseases.
- Understanding FI structure and function is crucial for managing complement-related disorders.
Abstract:
Factor I (FI) is a crucial inhibitor controlling all complement pathways due to its ability to degrade activated complement proteins C3b and C4b in the presence of cofactors such as factor H, C4b-binding protein, complement receptor 1 or CD46. Complete deficiency of FI, which is synthesized mainly in the liver is rare and leads to complement consumption resulting in recurrent severe infections, glomerulonephritis or autoimmune diseases. Incomplete FI deficiency is in turn associated with atypical haemolytic uremic syndrome, a severe disease characterized by thrombocytopenia, microangiopathic haemolytic anaemia and acute renal failure. Structurally, FI is a 88kDa heterodimer of a heavy chain consisting of one FI-membrane attack complex (FIMAC) domain, one CD5 domain and two low-density lipoprotein receptor domains (LDLr), and a light chain which is a serine protease domain (SP), linked to the heavy chain by a disulfide bond. FI cleaves its in vivo substrates C3b and C4b only in the presence of cofactors, it shows poor enzymatic activity towards synthetic substrates tested so far and it has no natural inhibitor.
More Related Videos
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
06:54Evaluation of the Interplay Between the Complement Protein C1q and Hyaluronic Acid in Promoting Cell Adhesion
Published on: June 15, 2019
Related Concept Videos
Complement System
Factors Affecting Illness
For instance, risk factors are connected to illness, disability,...
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin create...